CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-05 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −47,950 | $1.22 | $58K | 5,959,172 |
| 2025-11-05 | EVNIN LUKE Director | Sale 10b5-1 | −30,774 | $1.22 | $38K | 3,822,421 |
| 2025-11-04 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −140,488 | $1.22 | $171K | 6,007,122 |
| 2025-11-04 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −140,488 | $1.22 | $171K | 6,007,122 |
| 2025-11-04 | EVNIN LUKE Director | Sale 10b5-1 | −90,164 | $1.22 | $110K | 3,853,195 |
| 2025-11-03 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −94,063 | $1.29 | $121K | 6,147,610 |
| 2025-11-03 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −94,063 | $1.29 | $121K | 6,147,610 |
| 2025-11-03 | EVNIN LUKE Director | Sale 10b5-1 | −60,369 | $1.29 | $78K | 3,943,359 |
| 2025-10-31 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −114,044 | $1.28 | $146K | 6,241,673 |
| 2025-10-31 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −114,044 | $1.28 | $146K | 6,241,673 |
| 2025-10-31 | EVNIN LUKE Director | Sale 10b5-1 | −73,192 | $1.28 | $94K | 4,003,728 |
| 2025-10-30 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −86,936 | $1.43 | $124K | 6,355,717 |
| 2025-10-30 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −86,936 | $1.43 | $124K | 6,355,717 |
| 2025-10-30 | EVNIN LUKE Director | Sale 10b5-1 | −55,795 | $1.43 | $80K | 4,076,920 |
| 2025-10-29 | EVNIN LUKE Director | Sale 10b5-1 | −86,154 | $1.55 | $134K | 4,132,715 |
| 2025-10-29 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −134,240 | $1.55 | $208K | 6,442,653 |
| 2025-10-29 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −134,240 | $1.55 | $208K | 6,442,653 |
| 2025-10-28 | EVNIN LUKE Director | Sale 10b5-1 | −44,327 | $1.64 | $73K | 4,218,869 |
| 2025-10-28 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −69,068 | $1.64 | $113K | 6,576,893 |
| 2025-10-28 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −69,068 | $1.64 | $113K | 6,576,893 |
Page 8 of 17 · 335 trades